Poster: Expansion of human induced pluripotent stem cells in scalable stirred suspension culture
Posted: 12 January 2018 | Merck | No comments yet
Expansion of hiPSCs as aggregates in stirred suspension…
Background
- The cell concentrations recommended for clinical scale tissue engineering warrant the use of systems that are capable of generating large batches of human induced pluripotent
stem cells (hiPSCs) in a controlled manner. - Stirred suspension culture is a scalable method that has been used to successfully manufacture vaccines and therapeutic cells for numerous indications.
- Prior studies have shown the ability to culture hiPSCs in stirred suspension culture, however the culture vessels have mostly been limited to small scale spinner flasks.
Objective
- To grow hiPSCs as aggregates in 125mL spinner flasks and scale up to a 1L culture in a single-use bioreactor.
If you are viewing this poster in the USA or Canada, please click here to view the MilliporeSigma version.
The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada
This poster is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related content from this organisation
- Biotech leader champions targeted cancer treatments and diversity
- Product hub: Light the path to your next neuroscience discovery with a new ultrasensitive NF-L immunoassay
- A high-throughput macrodomain assay to identify coronavirus drugs
- Building a powerful portfolio of sepsis biomarker signatures for therapeutic clinical trials
- Drug Target Review Assays ebook 2022
Related topics
Cell Cultures, Stem Cells
Related organisations
Merck KGaA
